Logo Image
Feature|Articles|August 16, 2024

Pharmaceutical Executive

  • Pharmaceutical Executive: July/August 2024
  • Volume 44
  • Issue 7/8

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Follow the links below to read about each product:

Exxua (Fabre-Kramer Pharmaceuticals)

Omvoh (Eli Lilly)

Truqap (AstraZeneca)

Wegovy (Novo Nordisk)

Winrevair (Merck & Co.)

Articles in this issue

almost 2 years ago

Pharmaceutical Executive: July/August 2024 Issue (PDF)

almost 2 years ago

An AI Pulse Check

almost 2 years ago

A Promising Option: Exxua

almost 2 years ago

Opening the Door: Omvoh

almost 2 years ago

'Marked’ for Stardom?: Truqap

almost 2 years ago

Branching Off: Wegovy

almost 2 years ago

A Formidable First: Winrevair

almost 2 years ago

The Future of Launch Excellence is Generative AI

almost 2 years ago

From Potential to Value: Carving a Slice of the CGT ‘PIE'

almost 2 years ago

Big Bets, Bold Steps

Related Content